Trial reportJournal of clinical immunology2013
Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).
Trial report in Journal of clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review.Frontiers in immunology · 2023Pooled it
- Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.Frontiers in immunology · 2021Pooled it
- What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review.Frontiers in immunology · 2020Pooled it
- Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.Frontiers in immunology · 2021Trial
- Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Approach to diagnosing and managing granulomatous-lymphocytic interstitial lung disease.EClinicalMedicine · 2024Review
- Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review.Biomedicines · 2024Review
- Article
- Dysregulated Lymphocyte Antigen Receptor Signaling in Common Variable Immunodeficiency with Granulomatous Lymphocytic Interstitial Lung Disease.Journal of clinical immunology · 2023Article
- Non-infectious Pulmonary Complications in Children with Primary Immunodeficiency.Clinical medicine insights. Pediatrics · 2023Review
- Pulmonary Manifestations of Primary Humoral Deficiencies.Canadian respiratory journal · 2022Review
- Integrating Clinics, Laboratory, and Imaging for the Diagnosis of Common Variable Immunodeficiency-Related Granulomatous-Lymphocytic Interstitial Lung Disease.Frontiers in immunology · 2022Article
- Pulmonary Hypertension in Patients with Common Variable Immunodeficiency.Journal of clinical immunology · 2021Article
- Pulmonary granulomatosis of genetic origin.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- A functionally improved case of obstructive impairment caused by systemic lupus erythematosus.Breathe (Sheffield, England) · 2021Article
- Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency.Journal of clinical immunology · 2021Article
- Granulomatous-Lymphocytic Interstitial Lung Disease Mimicking Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021Article
- Editorial: Interstitial Lung Disease in Primary Immunodeficiencies.Frontiers in immunology · 2021Article
- Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers.Frontiers in immunology · 2021Article
- Interstitial Lung Disease in Common Variable Immunodeficiency.Frontiers in immunology · 2021Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
purposeA subset of patients with common variable immunodeficiency (CVID) develops granulomatous and lymphocytic interstitial lung disease (GLILD), a restrictive lung disease associated with early mortality. The optimal therapy for GLILD is unknown. This study was undertaken to see if rituximab and azathioprine (combination chemotherapy) would improve pulmonary function and/or radiographic abnormalities in patients with CVID and GLILD.
methodsA retrospective chart review of patients with CVID and GLILD who were treated with combination chemotherapy was performed. Complete pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans of the chest were done prior to therapy and >6 months later. HRCT scans of the chest were blinded, randomized, and scored independently (in pairs) by two radiologists. The differences between pre- and post-treatment HRCT scores and PFT parameters were analyzed.
resultsSeven patients with CVID and GLILD met inclusion criteria. Post-treatment increases were noted in both FEV1 (p=0.034) and FVC (p=0.043). HRCT scans of the chest demonstrated improvement in total score (p=0.018), pulmonary consolidations (p=0.041), ground-glass opacities (p=0.020) nodular opacities (p=0.024), and both the presence and extent of bronchial wall thickening (p=0.014, 0.026 respectively). No significant chemotherapy-related complications occurred.
conclusionsCombination chemotherapy improved pulmonary function and decreased radiographic abnormalities in patients with CVID and GLILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.